Diosgenin in Colon Cancer

Exclusively available on PapersOwl
Updated: Jul 03, 2021
Read Summary
Cite this
Category: Biology
Date added
Pages:  5
Words:  1359
Order Original Essay

How it works

Diosgenin in Colon Cancer essay

The author noted that constrain the 3-hydroxy-3-methylglutaryl CoA reductase expression and stimulate apoptosis by diosgenin in human colon tumor cells and also diosgenin is a potent inhibitor of HCT-116 with growth inhibition and induction of apoptosis [39]. Diosgenin tempt apoptosis via Cyclooxygenase-2 and 5-lipoxygenase trail in HT-29 and HCT-116 [40]. The author described the initial time that diosgenin improved 5-LOX activity and its inhibition by AA-861 radically reduced apoptosis of colorectal tumor cells.

Moreover, COX-2-expressing colorectal carcinoma cells were fewer sensitive to diosgenin tempted apoptosis related to COX-2 lacking colorectal cancer cells and up-regulation of COX-2 interpretation and activity in diosgenin tempted HT-29 cell damage and pre-treatment with a COX-2 selective inhibitor noticeably sensitized colon carcinoma cells expressing COX-2 to diosgenin-temped apoptosis but secluded HCT-116 cells [40]. The author suggested that death receptor-5 via activation of p38 pathway and endorse TRAIL-induced apoptosis in colon carcinoma cell by diosgenin and author showed that diosgenin sensitizes HT-29 cells to TRAIL-induced apoptosis in the mechanisms core this sensitization mostly involved diosgenin tempted p38 MAPK pathway activation and following DR5 over-expression. also, they showed that diosgenin alone/ TRAIL alone or combination action augmented COX-2 expression, and the purpose of a COX-2 inhibitor, also increased apoptosis [41].

Need a custom essay on the same topic?
Give us your paper requirements, choose a writer and we’ll deliver the highest-quality essay!
Order now

Author showed that Commercial diosgenin which limited diosgenin at 63.8 1.2 mg/ kg dry weight they showed in the diet at 10-100 concentration in 17 weeks that Groups of mice that conventional diosgenin all doses yielded radically less quantity of colon cancer they decide with the AOM/DSS-treated mice and they confirm that diosgenin suppressed colon cancer by lessening colonic swelling and serum triglyceride levels, up-regulating lipoprotein lipase and changing multiple signaling pathways [42]. The author proclaimed that reduce azoxymethane-induced aberrant crypt foci development in F344 rats and induce apoptosis in HT-29 cells. Diosgenin in hampers or retarding ACF development during initiation/ post-initiation and promotional stages of azoxymethane- persuade rat colon tumor. They figured out the result of diosgenin on reducing cell growth and change the expression of Bcl-2/caspase-3 in colon tumor cells [43].

The author declared that diosgenin tempted Sonic Hedgehog in megakaryocytic differentiation persuade in HEL cells, they showed up those diverse elements of the Hedgehog trail. Diosgenin triggers SHh production foremost to SMO expression and GLI commencement and inhibition of the SHh trail concerned during diosgenin persuade megakaryocytic differentiation [44]. Eliminate the influence of diosgenin by reducing the influence of identical cells that brief time exposure to diosgenin was able to persuade whole differentiation to maximal maturation [45]. Diosgenin persuade differentiation of HEL cells author focused particularly pleasing on expression of phosphorylated kinases such as Akt and MAPKs but also on process of the transcription factor NF-?B and author confirm that diosgenin persuade the megakaryocytic differentiation of Erythroleukemia Cancer cells throughout combined activation of the ERK signaling trail and the inventory of the p38/ MAPK trail [46]. Differentiated cells they established an apparent inhibition of survival factors NF-?B, AKT, and Bcl-2 and establishment of caspase-3 mutually with PARP cleavage foremost to apoptosis of diosgenin distinguished cells.

Author demonstrated that diosgenin induce ERK activation was involved in COX-2 high expression associated with the amount of megakaryocytic differentiated human erythroleukemia cancer cells through diosgenin treatment. Certainly, pretreatment of U0126 reduced the COX-2 overexpression tempted by diosgenin but further undermined the level of ploidy of human erythroleukemia cells and find out the probable exocrine activity of over produce prostanoids, they used PGE2 and TxA2 agonists and exogenous prostanoids [47].A proteomic approach to the understanding of molecular targets in following apoptosis of human erythroleukemia cancer cells [48]. The author described two distinct fractions they were assembled, F1and F3 .F1 had a high percentage of G2/M cells with p53 high expression, and F3 had a large rate of G1 cells with phospho-ERK over-expression. The combination of SdFFF cell division to a powerful imaging then explained that the F3 cells G1 phase were more sensitive to delineation and determined the peak retention changes, increase in cell size, and CD41 term. As F1 cells were declared to be less sensitive [49]. The author proved that a rise in intracellular calcium level induces cell cycle arrest and apoptosis in HEL by the activation of cPLA2 and COX-2 overexpression through the induction of diosgenin [50]

Diosgenin reducing MMps expression and too suppressed and PI3K/Akt ERK, JNK signaling pathways and NF-kB action restrain movement and aggression of PC-3 cells [51]. Diosgenin reduces the proliferation of prostate tumor cells (DU145) by triggering autophagy and apoptosis, and the method underlying this establishment may be associ¬ated among the overthrow of the PI3K/Akt and mTOR signaling trail. Moreover, Theon of autophagy arbitrate by diosgenin enhance apoptosis [52]

Diosgenin deregulates p65/p50, NF-?B p38, and MAPK trail and attenuates acute lung injury persuade by lipopolysaccharide in vivo and author noted that diosgenin significantly attenuates LPS-induced MAPK/ p38 and NF-?B establishment both in vitro and in vivo following lung infection and histopathological change in ALI model in in vivo [53]. The author indicated that the diosgenin restrains telomerase activity by free trade of hTERT gene expression in the lung carcinoma cell line [54]. The author proved that fenugreeks pull out diosgenin and unpolluted diosgenin reduce the hTERT gene expression in A549 cell line [55]. The author demonstrated that diosgenin has anti-proliferative and apoptotic assets mediated via the caspase, JNK and Akt way in squamous cells tumor cells lines such as A431 and Hep2 [56].

Author showed that sequence of 26-hydroxy-22-oxocholestanic frameworks as of and hecogenin and diosgenin their in vitro anti-proliferative and apoptotic action on human cervical carcinoma (CaSki) cells and these both systems did not alter essentially the proliferation of fibroblast cells, and, rarely, persuade peripheral blood lymphocytes to reproduce, analytic of an immunostimulatory outcome [57]. Induction of diosgenin antiproliferative effect via activation of p53, rescue of apoptosis-inducing factor and inflection of caspase-3 activity in various tumor cells. Diosgenin reducing cell growth among apoptosis and cell cycle arrest stimulation by p53 activation in various human tumor cell lines such as melanoma cells and laryngo cancer. Furthermore, a great part they focused on the mitochondrial form and diosgenin’s use was caspase-3 dependent, with a reduction of ??m and nuclear localization’ of AIF in the different tumor [58]

Diosgenin reduces melanogenesis via the activation of the PI3K signalling pathway [59]. Diosgenin persuade ROS-dependent autophagy and cytotoxicity through mTOR signaling system in chronic myeloid leukemia cells Moreover, diosgenin can ready to concurrently induce autophagy cytotoxicity in BaF3 –WT K562 cells, Diosgenin strongly raise ROS level, and this oxidative stress not only generate cytotoxic effect on in chronic myeloid leukemia cells but also tempted autophagy which act as a tolerance mechanism to defeat cytotoxicity of diosgenin in chronic myeloid leukemia cells through mTOR signaling pathway [60]. Diosgenin restrains osteoclastogenesis, proliferation, and aggression through the deregulation of Akt/PI3K kinase establishment and NF-kB-regulated gene expression [61]. The author reported that diosgenin tested the measuring of tumor extent, tumor size, and tumor burden and review the actions of detoxification agents, it used the point of lipid peroxidation by-products and antioxidants grade by precise colorimetric methods [62]. The author reported that diosgenin use a certain anti-invasion function on BGC-823 cells, which are susceptible to the hypoxia stimulus, and down-regulated HIF-1? might significantly progress its effects. The author proposes that combined with reduced HIF-1?, Diosgenin might be measured as a candidate to develop clinical therapy of gastric tumor [63].


Compounds derivative either from remedial or dietetic plant sources squeeze peculiar improvements, such as new bioactive structures, fewer toxicity, and various targeted in abrogating oncogenic evolution (Table-1); In this manner, they may form the resource of improved therapeutic choice. A vast body of preclinical investigational evidence proposes that diosgenin has huge possible as an anti-cancer mediator. In this review, we have collected and studied the role of diosgenin in adapting various monogenic transcription aspect and intracellular molecular aspect that force tumor initiation, development, and metastasis (Figure-3). The pharmacological feature of diosgenin gives the database of the pharmacological activity of diosgenin, its extraction and analytical procedure for the determination which can be effective for the researcher who wants to explore the hidden potential of this phytoconstituents. The collective information summarized in the review will act as an important segment for the development of effective medicines to treat cancer.”

The deadline is too short to read someone else's essay

Hire a verified expert to write you a 100% Plagiarism-Free paper

Cite this page

Diosgenin in Colon Cancer. (2021, Jul 03). Retrieved from https://papersowl.com/examples/diosgenin-in-colon-cancer/